Overview

A Study of TG103 Injection in Overweight/Obese Subjects Without Diabetes

Status:
Not yet recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess the safety and tolerability of multiple doses of TG103 injection in overweight/obese subjects without diabetes
Phase:
Phase 1
Details
Lead Sponsor:
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.